Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

BIO releases largest study ever on clinical development success rates

On Wednesday, BIO released the largest ever study of clinical development success rates. The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past decade, “Clinical Development Success Rates 2006-2015” compares groups of diseases, drug modalities and other attributes to generate the most comprehensive analysis, to date, of biopharmaceutical R&D success. “This study provides a wealth of information about drug development success rates Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Morning Consult: Medicare’s Deadly Cancer Care Gamble

new-bio-logo

Today in Morning Consult, cancer survivor and health economist Jennifer Hinkel writes about the threat posed to cancer patients by CMS’s proposed Medicare Part B drug payment model: Who will bear the most significant burden? It will be the poorest, oldest, and least educated patients who will struggle to understand whether they and their doctors have been assigned to the “experimental arm” of this reimbursement research trial. These Medicare beneficiaries will be the unwitting subjects Read More >

Health  |  Leave a comment  |  Email This Post
Tags: ,

Report Finds Increasing Number of 340B Hospitals Provide Minimal Charity Care

A new report released yesterday by the Alliance for Integrity and Reform of 340B (AIR340B), of which BIO is a member, found a dramatic decline in charity care provided by 340B hospitals in 2014, which was the first year of coverage expansion under the Affordable Care Act. The report found that over a third (37 percent) provided charity care representing less than 1 percent of total patient costs – far higher than the 24 percent Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Immune Deficiency Foundation: Medicare’s “one size fits all” drug demo is wrong for seniors with rare and chronic diseases

medical_research

Writing yesterday in The Hill, Immune Deficiency Foundation President Marcia Boyle explains the potential harm posed to patients by the recently proposed Medicare Part B demonstration: While CMS’ intent is to save money, the results of this demonstration stand to severely impact patients who rely on Medicare. The reduction in reimbursement will force many providers to stop offering the most clinically effective treatments, leaving patients with two options: forego prescribed therapies or travel to more expensive Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Report: Low Compliance with ACA Charity Care Requirements among 340B Hospitals

Earlier this week, the Alliance for Integrity and Reform of 340B, of which BIO is a member, released a new report examining hospitals’ compliance with the charity care requirements of the Affordable Care Act (ACA). The report found that large numbers of both 340B and non-340B hospitals are not complying with protections contained in the ACA for low-income patients, such as rules designed to ensure they are made aware of a hospital’s charity care program Read More >

Health  |  Leave a comment  |  Email This Post
Tags: ,